- $6.73bn
- $7.57bn
- $1.48bn
Alkermes rises after narcolepsy drug shows promise in mid-stage study
Brief: Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study Of Once-Daily Alixorexton IN PATIENTS WITH NARCOLEPSY TYPE 1
Brief: Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study
Alkermes Plc reports results for the quarter ended March 31 - Earnings Summary
Brief: Alkermes Q1 Revenue USD 306.5 Million Vs. IBES Estimate USD 304.1 Million
Brief: Alkermes - CFO Iain M. Brown Passes Away - SEC Filing
Brief: Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia
Brief: Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Alkermes rises on Q4 sales beat
Alkermes Plc reports results for the quarter ended December 31 - Earnings Summary
Alkermes Plc reports results for the quarter ended in September 30 - Earnings Summary
Alkermes Plc expected to post earnings of 73 cents a share - Earnings Preview
Brief: Alkermes Announces Initiation Of Vibrance-2 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Narcolepsy Type 2
Alkermes Plc reports results for the quarter ended in January - Earnings Summary
Alkermes Plc expected to post earnings of 70 cents a share - Earnings Preview
Alkermes Plc expected to post earnings of 70 cents a share - Earnings Preview
Brief: Alkermes Sells Athlone, Ireland Facility To Novo Nordisk
Alkermes Plc reports results for the quarter ended in March - Earnings Summary
Brief: Alkermes plc Reports First Quarter 2024 Financial Results